On September 30 2023, AMYLYX PHARMACEUTICALS ($NASDAQ:AMLX) announced their results for FY2023 Q3, showing a staggering increase in both total revenue and net income. Similarly, net income rose 138.9%, with a total of USD 20.9 million.
On Thursday, AMYLYX PHARMACEUTICALS reported record-breaking FY2023 Q3 earnings results with the stock opening at $12.7 and closing at $12.3, a plunge of 31.9% from its last closing price of 18.0. The significant drop in its stock price came as a surprise to markets, especially considering the company’s financial growth in the past year. Despite these impressive numbers, the market reaction to the quarterly report was largely negative. Analysts have speculated that the drop in stock price could be attributed to investors’ concerns about the potential for future growth and competition from other pharmaceutical companies.
The company has yet to comment on the sudden dip in its stock price, but the financial performance of AMYLYX PHARMACEUTICALS in the previous year suggests that this performance should not be seen as indicative of future trends. It remains to be seen if the stock will continue to trend downward or if it will rebound in the near future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Amylyx Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Amylyx Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Amylyx Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Amylyx Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have thoroughly analyzed the financials of AMYLYX PHARMACEUTICALS. Our Star Chart shows that the company is strong in terms of assets and growth, but weak in dividend and profitability. We gave AMYLYX PHARMACEUTICALS an intermediate health score of 6/10 due to its cashflows and debt. This means the company might be able to pay off its debt and fund future operations. Investors who are looking for a higher risk but higher return may be interested in investing in such a company. More…
Star Chart Analysis
The Company focuses on the development and commercialization of therapeutics for the treatment of neurological disorders. Its product candidates include AMY-101 and AMY-105. AMY-101 is a small molecule that inhibits neuronal cell death. AMY-105 is a small molecule that modulates the unfolded protein response. The Company’s other product candidates include AMY-202 and AMY-203. The Company operates in the United States. Annovis Bio Inc is a clinical stage neuroscience company developing novel therapies for Alzheimer’s disease, Parkinson’s disease and other neurological diseases. Annovis’ lead product candidate, ANVS-401, is in a Phase 2 clinical trial for Alzheimer’s disease. ANVS-401 targets beta amyloid, the main protein involved in Alzheimer’s disease. Oyster Point Pharma Inc is a clinical stage biopharmaceutical company developing therapies for glaucoma, idiopathic intracranial hypertension and other eye diseases. Oyster Point’s lead product candidate, OC-01, is in Phase 2 clinical trials for the treatment of glaucoma. OC-01 is a topical eye drop that reduces intraocular pressure by targeting Rho kinase, a key protein involved in the development of glaucoma. Corbus Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company developing therapies for the treatment of rare, life-threatening and chronic inflammatory diseases. Corbus’ lead product candidates are lenabasum and anabasum. Lenabasum is in Phase 3 clinical trials for the treatment of systemic sclerosis and cystic fibrosis. Anabasum is in Phase 2 clinical trials for the treatment of dermatomyositis and systemic lupus erythematosus.
Anovis Bio Inc is a publicly traded company that focuses on the development and commercialization of novel therapeutics to treat patients with cancer. The company’s market cap is $101.89M and its ROE is -37.92%. Anovis Bio Inc has a strong focus on R&D and has a number of ongoing clinical trials for its lead candidate, ANVS-401. The company is also advancing a number of other programs in its pipeline.
– Oyster Point Pharma Inc ($NASDAQ:OYST)
Oyster Point Pharma Inc is a pharmaceutical company that focuses on the development and commercialization of therapies to treat eye diseases. The company has a market capitalization of $224.04 million and a return on equity of -276.35%. Oyster Point Pharma Inc is headquartered in New York, New York.
– Corbus Pharmaceuticals Holdings Inc ($NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company’s lead product is anabasum, which is in Phase 3 clinical trials for the treatment of systemic sclerosis and dermatomyositis. Corbus Pharmaceuticals Holdings Inc has a market cap of 15.9M as of 2022, a Return on Equity of -44.89%. The company’s focus on developing therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases gives it a strong potential growth area, but its high ROE indicates that it is currently not generating sufficient profits to cover its costs of equity.
AMYLYX PHARMACEUTICALS reported strong financial results for fiscal year 2023 Q3, with total revenue increasing to USD 102.7 million and net income up 138.9% year over year to USD 20.9 million. Despite these impressive figures, the company’s stock price dropped the same day, indicating investors may be expecting greater returns in future quarters. It remains to be seen whether or not AMYLYX can maintain its positive financial performance, but for now investors should proceed with caution until further evidence of profitability is available.